Tisotumab Vedotin (HuMax-TF-ADC)

Phase 2

Seagen Inc. (SGEN)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Ovary Cancer

View Full Landscape

Drug Information

Target Indication

Ovary Cancer

Clinical Trial

NCT02001623

Last updated: 12/3/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/28/2025

Tivdak

Tivdak as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy (see section 5.1).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SGEN

Seagen Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

PadcevPhase 3

Urothelial Cancer

sigvotatug vedotinPhase 3

Carcinoma, Non-Small-Cell Lung

tucatinibPhase 3

Gastric Adenocarcinoma

brentuximab vedotinPhase 3

Lymphoma, B-Cell

disitamab vedotinPhase 3

Breast Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts